FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027795491> ?p ?o ?g. }

• W2027795491 endingPage "e0123617" @default.
• W2027795491 startingPage "e0123617" @default.
• W2027795491 abstract "Objective The risk factors of bladder cancer recurrence after transurethral resection of bladder tumor (TURBt) were poorly understood, especially in Chinese population. This study evaluated the potential risk factors of recurrence based on a Chinese population. Materials and Methods A total of 698 patients that received TURBt procedure in our institute from 2000 to 2012 were recruited in this study. Clinical information was collected. The patients were followed up according to the schedule recommended by Chinese guideline. Results A total of 583 males (83.5%) and 115 females (16.5%) were enrolled in our study. The median follow-up duration was 51.5 months. Gender, chief complain, tumor size, number of lesions, histological grade and chemotherapeutic agents were found significantly associated with patients’ short-term recurrence (less than 1 year) (All p<0.05). In the multivariate analysis, tumor size, number of lesions, histological grade and chemotherapeutic agents were significantly related to patients’ short-term recurrence (less than 1 year) (All p<0.05). A multivariate model based on tumor size, number of lesions, histological grade and chemotherapeutic agents had an AUC of 0.697, which significantly improved the prediction utility for bladder cancer short-term recurrence (less than 1 year) than any single factor In the multivariate Cox regression, tumor size greater than 3 cm, multifocal lesions, worsen histological grade and non-urothelial carcinoma was related to time to recurrence (TR). Conclusion Patients with larger tumor size, multifocal number of lesions, higher tumor grade and who received chemotherapeutic agents other than Epirubicin and Pirarubicin might have higher risks of recurrence less than 1 year. Tumor size, number of lesions, pathology and histological grade might be associated with TR. As Bacille Calmette-Guerin (BCG) is currently not approved for bladder cancer in China, Epirubicin and Pirarubicin might be considered prior to other chemotherapy medications when providing post-operative instillation of chemotherapy." @default.
• W2027795491 created "2016-06-24" @default.
• W2027795491 creator A5004304551 @default.
• W2027795491 creator A5005460814 @default.
• W2027795491 creator A5031205173 @default.
• W2027795491 creator A5038254219 @default.
• W2027795491 creator A5039786650 @default.
• W2027795491 creator A5055736577 @default.
• W2027795491 creator A5057647448 @default.
• W2027795491 creator A5075256301 @default.
• W2027795491 creator A5077791617 @default.
• W2027795491 creator A5084234415 @default.
• W2027795491 date "2015-04-07" @default.
• W2027795491 modified "2023-10-16" @default.
• W2027795491 title "The Evaluation of the Risk Factors for Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence after Transurethral Resection (TURBt) in Chinese Population" @default.
• W2027795491 cites W1482328974 @default.
• W2027795491 cites W1711618159 @default.
• W2027795491 cites W1971950388 @default.
• W2027795491 cites W1976579584 @default.
• W2027795491 cites W2002045993 @default.
• W2027795491 cites W2017306423 @default.
• W2027795491 cites W2019104867 @default.
• W2027795491 cites W2052562958 @default.
• W2027795491 cites W2060494387 @default.
• W2027795491 cites W2069052988 @default.
• W2027795491 cites W2077840948 @default.
• W2027795491 cites W2082632361 @default.
• W2027795491 cites W2083960385 @default.
• W2027795491 cites W2101014663 @default.
• W2027795491 cites W2104864065 @default.
• W2027795491 cites W2111442523 @default.
• W2027795491 cites W2151781453 @default.
• W2027795491 cites W2162130153 @default.
• W2027795491 cites W2165543889 @default.
• W2027795491 cites W2165798394 @default.
• W2027795491 cites W2169961966 @default.
• W2027795491 cites W2219978888 @default.
• W2027795491 cites W4245346161 @default.
• W2027795491 doi "https://doi.org/10.1371/journal.pone.0123617" @default.
• W2027795491 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4388336" @default.
• W2027795491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25849552" @default.
• W2027795491 hasPublicationYear "2015" @default.
• W2027795491 type Work @default.
• W2027795491 sameAs 2027795491 @default.
• W2027795491 citedByCount "25" @default.
• W2027795491 countsByYear W20277954912016 @default.
• W2027795491 countsByYear W20277954912018 @default.
• W2027795491 countsByYear W20277954912020 @default.
• W2027795491 countsByYear W20277954912021 @default.
• W2027795491 countsByYear W20277954912022 @default.
• W2027795491 countsByYear W20277954912023 @default.
• W2027795491 crossrefType "journal-article" @default.
• W2027795491 hasAuthorship W2027795491A5004304551 @default.
• W2027795491 hasAuthorship W2027795491A5005460814 @default.
• W2027795491 hasAuthorship W2027795491A5031205173 @default.
• W2027795491 hasAuthorship W2027795491A5038254219 @default.
• W2027795491 hasAuthorship W2027795491A5039786650 @default.
• W2027795491 hasAuthorship W2027795491A5055736577 @default.
• W2027795491 hasAuthorship W2027795491A5057647448 @default.
• W2027795491 hasAuthorship W2027795491A5075256301 @default.
• W2027795491 hasAuthorship W2027795491A5077791617 @default.
• W2027795491 hasAuthorship W2027795491A5084234415 @default.
• W2027795491 hasBestOaLocation W20277954911 @default.
• W2027795491 hasConcept C121608353 @default.
• W2027795491 hasConcept C126322002 @default.
• W2027795491 hasConcept C126894567 @default.
• W2027795491 hasConcept C143998085 @default.
• W2027795491 hasConcept C2776085618 @default.
• W2027795491 hasConcept C2776694085 @default.
• W2027795491 hasConcept C2780352672 @default.
• W2027795491 hasConcept C2780835546 @default.
• W2027795491 hasConcept C2908647359 @default.
• W2027795491 hasConcept C2992225637 @default.
• W2027795491 hasConcept C38180746 @default.
• W2027795491 hasConcept C50382708 @default.
• W2027795491 hasConcept C530470458 @default.
• W2027795491 hasConcept C71924100 @default.
• W2027795491 hasConcept C77350462 @default.
• W2027795491 hasConcept C99454951 @default.
• W2027795491 hasConceptScore W2027795491C121608353 @default.
• W2027795491 hasConceptScore W2027795491C126322002 @default.
• W2027795491 hasConceptScore W2027795491C126894567 @default.
• W2027795491 hasConceptScore W2027795491C143998085 @default.
• W2027795491 hasConceptScore W2027795491C2776085618 @default.
• W2027795491 hasConceptScore W2027795491C2776694085 @default.
• W2027795491 hasConceptScore W2027795491C2780352672 @default.
• W2027795491 hasConceptScore W2027795491C2780835546 @default.
• W2027795491 hasConceptScore W2027795491C2908647359 @default.
• W2027795491 hasConceptScore W2027795491C2992225637 @default.
• W2027795491 hasConceptScore W2027795491C38180746 @default.
• W2027795491 hasConceptScore W2027795491C50382708 @default.
• W2027795491 hasConceptScore W2027795491C530470458 @default.
• W2027795491 hasConceptScore W2027795491C71924100 @default.
• W2027795491 hasConceptScore W2027795491C77350462 @default.
• W2027795491 hasConceptScore W2027795491C99454951 @default.
• W2027795491 hasIssue "4" @default.
• W2027795491 hasLocation W20277954911 @default.
• W2027795491 hasLocation W20277954912 @default.

• next